Charles Schwab Investment Management Inc Lineage Cell Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 365,952 shares of LCTX stock, worth $365,952. This represents 0.0% of its overall portfolio holdings.
Number of Shares
365,952
Previous 363,215
0.75%
Holding current value
$365,952
Previous $395,000
36.96%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding LCTX
# of Institutions
124Shares Held
93.5MCall Options Held
21.4KPut Options Held
0-
Broadwood Capital Inc New York, NY41.7MShares$41.7 Million4.66% of portfolio
-
Black Rock Inc. New York, NY8.49MShares$8.49 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.37MShares$8.37 Million0.0% of portfolio
-
Logos Global Management LP San Francisco, CA6.25MShares$6.25 Million0.86% of portfolio
-
Defender Capital, Llc.4.97MShares$4.97 Million2.61% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $170M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...